Skip to main content
SpringerLink
Log in

Perorale zielgerichtete Tumortherapeutika

Dosisanpassung bei Leber- und Niereninsuffizienz

Oral targeted anti-cancer drugs

Dose optimization in hepatic and renal insufficiency

  • Onkologische Pharmazie
  • Published:
best practice onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Herbrink M, Nuijen B, Schellens J et al (2015) Variability in biovailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 41:412–422

    Article  CAS  PubMed  Google Scholar 

  2. Herviou P, Thivat E, Richard D et al (2016) Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncol Lett 12:1223–1232

    PubMed  PubMed Central  Google Scholar 

  3. De Wit D, Guchelaar HJ, den Hartigh J et al (2015) Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discov Today 1:18–36

    Article  Google Scholar 

  4. Parham LR, Briley LP, Li L et al. (2016) Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1 07:01. Pharmacogenomics J 16:180–185

    Article  CAS  PubMed  Google Scholar 

  5. Wind S, Schnell D, Ebner T et al (2017) Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clin Pharmacokinet 56:235–250

    Article  CAS  PubMed  Google Scholar 

  6. Bridoux F, Chen N, Moreau S et al (2016) Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. Cancer Chemother Pharmacol 78:173–182

    Article  CAS  PubMed  Google Scholar 

  7. Scott LJ (2014) Pomalidomide: a review of its use in patients with recurrent multiple myeloma. Drugs 74:549–562

    Article  CAS  PubMed  Google Scholar 

  8. Albarmawi A, Czock D, Gauss A et al (2014) CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol 77:160–169

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsapotheke, Röntgenweg 9, 72076, Tübingen, Deutschland

    H.-P. Lipp

Authors
  1. H.-P. Lipp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H.-P. Lipp.

Ethics declarations

Interessenkonflikt

H.P. Lipp gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lipp, HP. Perorale zielgerichtete Tumortherapeutika. best practice onkologie 12, 104–109 (2017). https://doi.org/10.1007/s11654-017-0016-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-017-0016-z

Search

Navigation